SCN2A and SCN8A Epilepsy and Relutrigine, Why Your Child's Variant Type Matters Before the December 27th FDA Decision

Which children with SCN2A or SCN8A epilepsy could relutrigine actually help, if the FDA approves it on December 27th? Nobody can answer that for a particular child until the label is written, but the trial behind the application gives a strong clue. It chose children by when their seizures began and left out children whose variant is known or presumed to switch the sodium channel down rather than up.

That split, called gain of function versus loss of function, already shapes which seizure medicines neurologists reach for in these two genes. Standard genetic test reports say whether a variant causes disease, not which way it moves the channel. The weeks before the decision are a good time for parents, guardians and caregivers to find out what their child's care team thinks.

Relutrigine's December 27th Decision, and Why the FDA Took 3 More Months

Relutrigine is a once-daily medicine from Praxis Precision Medicines, taken by mouth or through a feeding tube. It is under priority review for SCN2A and SCN8A developmental and epileptic encephalopathy, with a decision due December 27, 2026. The FDA accepted the application on March 30, 2026 with a September 27th target, according to Praxis.

That date moved after Praxis sent what it called additional sensitivity analyses of its existing trial data, which the FDA treated as a major amendment. Praxis said in June that no new studies were requested and that the FDA cited no safety or manufacturing concerns. By August the company reported a mid-cycle meeting with no major concerns identified so far and no advisory committee planned. On November 9th it said the review was still under way.

An approval would make relutrigine the first medicine for these two conditions, according to Praxis. It would also earn the company a pediatric review voucher, a transferable credit the FDA gives for rare childhood disease approvals. The full decision history lives on Trial Friend's relutrigine decision page, which updates the day the FDA acts.

The 53% figure Praxis reports comes from a design that is easy to misread. In the registration group of the EMBOLD study, 53 children were randomly assigned to 1 of 2 schedules. That count comes from Praxis's April 2026 poster at the American Academy of Neurology meeting.

Of those children, 28 took relutrigine for all 16 weeks. The other 25 took relutrigine for 12 weeks and a look-alike placebo for 4 weeks, with neither families nor doctors told when the placebo stretch fell. Every child in the trial therefore took relutrigine for at least 12 weeks.

Praxis compared seizures during relutrigine time, which it counts across 51 children, with seizures during those 4 hidden placebo weeks in 25 children. Measured that way, motor seizures fell 53% and motor seizure-free days rose 66%, and the company says both results were statistically significant. The study's data monitoring committee recommended stopping early for efficacy after a planned interim analysis, and Praxis stopped it.

Side effects were mostly mild or moderate, according to Praxis, and fever, colds and sleepiness were the most common. Praxis reports these as rates per 100 months of exposure rather than as a share of children, so they cannot be read as percentages. Among children assigned to the placebo schedule, the poster lists 1 withdrawal of consent and 1 death. It states that every serious adverse event was judged unrelated to relutrigine, without giving a cause.

“placebo period timing blinded to families and investigators”

Praxis Precision Medicines, EMBOLD poster, American Academy of Neurology 2026

None of this has appeared as a full peer-reviewed trial paper yet. The fullest public summary is a 2026 conference report in the journal Epilepsia, written by Praxis staff. A few of its details differ from the company's posters, including whether any child stopped because of a side effect.

Gain or Loss of Function, the SCN2A and SCN8A Split Behind the Trial

SCN2A and SCN8A each carry the instructions for a sodium channel in nerve cells, Nav1.2 and Nav1.6, the gates that let neurons fire. A gain-of-function variant leaves the channel too active, and a loss-of-function variant leaves it weaker or absent, according to MedlinePlus and The Cute Syndrome Foundation.

Researchers have tied each direction to a different age at first seizure. In SCN2A, a 2017 study in the journal Brain linked onset before 3 months of age with gain of function and later onset with loss of function. A 2024 study of 81 people, recruited through the FamilieSCN2A Foundation, found gain-of-function and mixed variants concentrated in seizures that began in the first month of life.

Loss of function is the more common direction in SCN2A. The FamilieSCN2A Foundation puts it at close to 80% of disease-causing variants, and many of those children have autism or intellectual disability with later seizures or none. In SCN8A, a 2022 study of 392 people found a median onset of 4 months in the focal epilepsy groups, where every lab-tested variant was gain of function. Generalized epilepsy, the main pattern with loss of function, began later, at a median of 42 months.

The EMBOLD listing on ClinicalTrials.gov turns that research into entry rules. Children with SCN2A had to have had their first seizure in the first 3 months of life. Children with SCN8A needed both a clinical and a genetic diagnosis of SCN8A developmental and epileptic encephalopathy. The trial excluded anyone with a documented or presumed loss-of-function variant, or with seizures that had worsened on an earlier sodium channel blocker.

Those rules shaped who took part, according to the AAN 2026 poster. In the group Praxis counted as treated, 38 of 51 children had SCN8A and 13 had SCN2A. Of those 51, 30 had their first seizure by 3 months of age.

Why Age at First Seizure Predicts Sodium Channel Blocker Response in SCN2A

Phenytoin, lacosamide, carbamazepine and oxcarbazepine all calm overactive sodium channels, which is why they are called sodium channel blockers. Relutrigine works on the same channels, so the record of those older drugs in SCN2A and SCN8A is the closest public guide to what variant type might mean for it.

That record follows the age at first seizure closely, at least in SCN2A. In the 2024 Brain study, phenytoin worked well for 17 of 18 children whose seizures began in the first month, and for none of 10 with later onset. Lacosamide followed the same pattern, working for 8 of 14 early-onset children and none of 7 with later onset.

Worsening is the other half of the story. In a 2022 study from 2 Chinese centers, oxcarbazepine made seizures worse in all 3 children whose seizures began after age 1. A 2026 Epilepsia study of people with loss-of-function SCN2A variants found seizures worsened in 16 of 53 tries of a sodium channel blocker, while 12 tries helped.

The researchers do not fully agree on why. The authors of the 2024 study found that response tracked age at first seizure, not the lab-measured function of each variant. Some newborn-onset children with loss-of-function variants still did well on phenytoin. A 2023 laboratory study added that many epilepsy variants show a mix of gain and loss that a simple 2-way label does not capture.

For SCN8A, a 2024 international consensus of clinicians and caregivers called sodium channel blockers the best first choice for gain-of-function and early-onset forms. The same panel called them relatively contraindicated in loss of function. Praxis is also testing elsunersen, an antisense medicine for gain-of-function SCN2A with seizures before 3 months. Its phase 3 study takes children from birth to 18 years at 6 recruiting US sites, according to its ClinicalTrials.gov listing (NCT07019922).

Reading an SCN2A or SCN8A Genetic Report for Variant Type

A genetic test report sorts a variant into 1 of 5 standard groups, from pathogenic to benign, under rules set by the American College of Medical Genetics and Genomics. Those groups answer whether a variant causes disease, not whether it turns the channel up or down.

Measuring direction takes a laboratory test called patch clamping, which records the current through a single channel. ClinGen is the NIH-funded program that writes gene-specific rules for classifying variants. Its 2026 sodium channel panel wrote that these results come from research laboratories, cannot be ordered from clinical labs, and are missing for most new variants.

Without a lab result, doctors work from clues in the variant and the child's history. Nonsense and frameshift variants, which cut the protein short, usually mean loss of function, and the EMBOLD trial treated them that way. A missense change, which swaps a single building block, can go either way. A 2022 study in Brain estimated up to a 92% likelihood that lab results for an identical variant in a related sodium channel gene apply to a new one.

• Is my child's variant thought to be gain of function, loss of function, mixed or unknown, and is that from a lab test, the variant type or the age seizures began?
• Is it a missense change or a truncating one, such as nonsense or frameshift?
• Has this exact variant, or one in the same spot of a related sodium channel gene, been studied in a lab?
• If the report says likely pathogenic or uncertain significance, how would we hear if that changes?
• Did any sodium channel blocker my child has taken make seizures better or worse, and what does that suggest?
• If relutrigine is approved, would my child's variant and seizure history fit the people it was tested in?

The FamilieSCN2A Foundation says it can connect clinicians with an international network of experts who help interpret variants. The research team behind the SCN Portal publishes tested sodium channel variants online. For SCN8A families, The Cute Syndrome Foundation explains the 2 variant directions in plain language.

Ztalmy and Fintepla, 2 Recent Genetic Epilepsy Approvals, and the Weeks That Followed

Two recent approvals show what happened between an FDA letter and a first bottle for a genetic epilepsy. Ztalmy became the first medicine approved for CDKL5 deficiency disorder in March 2022, and Fintepla was approved for Dravet syndrome in June 2020.

Trial Friend lined up 6 public plan policies, 3 for each drug, and found that none sets a minimum number of seizures. All 6 approve the medicine a year at a time. FEP Blue first dated its Ztalmy policy April 15, 2022, more than 3 months before launch, so the rules were waiting when the medicine arrived.

Nothing public yet says whether relutrigine will need a safety program, a controlled-substance listing or proof of a specific variant. Praxis said in August that it was building a patient support program and talking with payers. For Ztalmy, the plans asked for a genetic report naming the variant, a record of other seizure medicines and a neurologist's involvement. Trial Friend's first 90 days guides show how that kind of paperwork moved for other rare disease launches.

Relutrigine, SCN2A and SCN8A in Short Answers